NUCLIDIUM receives second Innosuisse grant for its precision imaging platform
Nuclidium has won a second Innosuisse Grant of €800.000 to improve treatment of carcinomas via precision imaging of the tumour microenvironment with a novel Copper-61-based PET tracer. Our Kalios program is targeting cells in the tumor microenvironment called cancer-associated fibroblasts, which are present in epithelial tumours such as breast and lung cancer and are not present in healthy tissues.